KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non Operating Income: 2017-2025

Historic Non Operating Income for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to -$75.6 million.

  • Amneal Pharmaceuticals' Non Operating Income fell 2.97% to -$75.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$289.2 million, marking a year-over-year increase of 6.97%. This contributed to the annual value of -$304.3 million for FY2024, which is 24.40% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Non Operating Income stood at -$75.6 million for Q3 2025, which was down 26.66% from -$59.7 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Non Operating Income high stood at -$27.5 million for Q4 2021, and its period low was -$97.7 million during Q4 2023.
  • In the last 3 years, Amneal Pharmaceuticals' Non Operating Income had a median value of -$64.8 million in 2024 and averaged -$67.9 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Non Operating Income soared by 30.25% in 2021, and later tumbled by 123.53% in 2023.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Non Operating Income stood at -$27.5 million in 2021, then slumped by 58.90% to -$43.7 million in 2022, then slumped by 123.53% to -$97.7 million in 2023, then climbed by 6.70% to -$91.1 million in 2024, then fell by 2.97% to -$75.6 million in 2025.
  • Its last three reported values are -$75.6 million in Q3 2025, -$59.7 million for Q2 2025, and -$62.9 million during Q1 2025.